COMPASS Pathways plc (CMPS)
| Previous close | 8.50 |
| Open | 8.56 |
| Bid | 8.58 x 100 |
| Ask | 8.64 x 200 |
| Day's range | 8.21 - 8.85 |
| 52-week range | 5.01 - 12.75 |
| Volume | |
| Avg. volume | 648,560 |
| Market cap | 587.062M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Compass Pathways Announces First Quarter 2024 Financial Results and Business Highlights
COMP360 phase 3 pivotal program in treatment-resistant depression (TRD) on track for top-line COMP005 trial data in fourth quarter 2024, COMP006 trial top-line data expected mid-2025Compass announces positive phase 2 COMP360 data in post-traumatic stress disorder (PTSD)Michael Gold to join Compass as Head of R&DCompass enters into additional commercial collaborations, including with Reliant Medical Group, part of Optum Care Cash position of $262.9 million at March 31, 2024 Conference call May 8
- GlobeNewswire
Compass Pathways announces durable improvement in symptoms through 12 weeks in open-label phase 2 study of COMP360 psilocybin in post-traumatic stress disorder
Study met primary safety endpoint; administration was well tolerated, with no serious adverse events observed Early and clinically meaningful improvement from baseline in mean CAPS-5 total score (29.5 point reduction at week 12), with change from baseline in mean SDS total score (14.4 point reduction at week 12)81.8% response (reduction of ≥ 15 points in CAPS-5 score), 63.6% remission (total CAPS-5 ≤ 20) rates at week 4 with 77.3% response and 54.5% remission at week 12 Measures of symptom score
- GlobeNewswire
Compass Pathways to announce first quarter financial results on May 8, 2024
LONDON, May 03, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the first quarter 2024 ending March 31, 2024, and provide an update on recent business developments, on May 8, 2024. The management team will host a conference call at 8:00 am ET (1:00 pm UK) on May 8, 2024. To access the call, please register in adva
